Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for ...

The campaign is based on the results of a survey that reveals the experiences of patients and caregivers in their communities ...

According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.

Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

Genentech and Novartis have teamed up with Food Allergy Research & Education (FARE) to enhance the safety of children with ...

Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero ...

The Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

We recently published a list of 12 Best Global Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

Novartis AG's ( VTX:NOVN ) dividend will be increasing from last year's payment of the same period to $3.50 on 13th ...

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...

Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its ...